{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:54:02Z","timestamp":1772520842773,"version":"3.50.1"},"reference-count":50,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Lymphovascular invasion is an adverse pathologic feature in prostate cancer, but its independent molecular drivers remain unclear due to strong confounding by tumor grade and stage. We performed a confounder-adjusted transcriptomic analysis of 403 TCGA-PRAD samples. Differential expression was adjusted for Gleason score and pathological T stage. A transcriptional profile associated with LVI was derived and tested in multivariable logistic and Cox proportional hazards models for biochemical recurrence-free survival, with bootstrap internal validation. After multivariable adjustment, 129 genes were independently associated with LVI. This gene set was overwhelmingly enriched for interferon-alpha\/beta signaling and antiviral response pathways. A continuous composite score derived from this profile predicted a reduced risk of biochemical recurrence independently of standard clinicopathological factors (adjusted HR per unit = 0.911, 95% CI: 0.835\u20130.993, p = 0.033). Multi-omics integration revealed subtle promoter hypomethylation and strong correlations between methylation and expression for key interferon genes, supporting transcriptional regulation. We identify a robust, interferon-response transcriptional profile that specifically defines LVI in prostate cancer after accounting for major clinical confounders. This transcriptional signature provides independent prognostic information, refines the biological understanding of LVI, and presents a novel targetable pathway for further investigation.<\/jats:p>","DOI":"10.3390\/ijms27052167","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:31:32Z","timestamp":1772098292000},"page":"2167","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Interferon-Response Transcriptomic Signature of Lymphovascular Invasion in Prostate Cancer"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9125-6444","authenticated-orcid":false,"given":"Cagdas","family":"Aktan","sequence":"first","affiliation":[{"name":"Department of Medical Biology, Faculty of Medicine, Bandirma Onyedi Eylul University, Balikesir 10250, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7593-7184","authenticated-orcid":false,"given":"Christina M.","family":"Breneman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2884-7243","authenticated-orcid":false,"given":"Okan","family":"Argun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Seeley","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ceren","family":"Atalar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendall","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari S.","family":"Hilibrand","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-6548","authenticated-orcid":false,"given":"Sophia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8963-6176","authenticated-orcid":false,"given":"Swati","family":"Mamidanna","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0101-0951","authenticated-orcid":false,"given":"Mutlay","family":"Sayan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e13537","DOI":"10.1097\/MD.0000000000013537","article-title":"The impact of lymphovascular invasion in patients with prostate cancer following radical prostatectomy and its association with their clinicopathological features: An updated PRISMA-compliant systematic review and meta-analysis","volume":"97","author":"Jiang","year":"2018","journal-title":"Medicine"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Sathianathen, N.J., Furrer, M.A., Mulholland, C.J., Katsios, A., Soliman, C., Lawrentschuk, N., Peters, J.S., Zargar, H., Costello, A.J., and Hovens, C.M. (2023). Lymphovascular Invasion at the Time of Radical Prostatectomy Adversely Impacts Oncological Outcomes. Cancers, 16.","DOI":"10.3390\/cancers16010123"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2018.05.034","article-title":"Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer","volume":"74","author":"Wilczak","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chung, D.H., Han, J.H., Jeong, S.H., Yuk, H.D., Jeong, C.W., Ku, J.H., and Kwak, C. (2023). Role of lymphatic invasion in predicting biochemical recurrence after radical prostatectomy. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1226366"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kang, Y.J., Kim, H.S., Jang, W.S., Kwon, J.K., Yoon, C.Y., Lee, J.Y., Cho, K.S., Ham, W.S., and Choi, Y.D. (2017). Impact of lymphovascular invasion on lymph node metastasis for patients undergoing radical prostatectomy with negative resection margin. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3307-4"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2332900","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate Cancer: A Review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.urology.2006.02.004","article-title":"Lymphovascular invasion in radical prostatectomy specimens: Prediction of adverse pathologic features and biochemical progression","volume":"68","author":"Loeb","year":"2006","journal-title":"Urology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Karwacki, J., \u0141\u0105tkowska, M., Jarocki, M., Jaworski, A., Szuba, P., Poterek, A., Lemi\u0144ski, A., Kaczmarek, K., Ha\u0142o\u0144, A., and Szyde\u0142ko, T. (2024). The clinical meaning of lymphovascular invasion: Preoperative predictors and postoperative implications in prostate cancer\u2014A retrospective study. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1349536"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4103\/1008-682X.156636","article-title":"The prognostic value of lymphovascular invasion in radical prostatectomy: A systematic review and meta-analysis","volume":"18","author":"Huang","year":"2016","journal-title":"Asian J. Androl."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/01.ju.0000113249.82533.28","article-title":"Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy","volume":"171","author":"Shariat","year":"2004","journal-title":"J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Karwacki, J., Gurwin, A., Jaworski, A., Jarocki, M., Stodolak, M., D\u0142ubak, A., Szuba, P., Lemi\u0144ski, A., Kaczmarek, K., and Ha\u0142o\u0144, A. (2024). Association of Lymphovascular Invasion with Lymph Node Metastases in Prostate Cancer-Lateralization Concept. Cancers, 16.","DOI":"10.3390\/cancers16050925"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chan, J., Tuac, Y., Argun, O., Breneman, C.M., Seeley, N., Moriarty, H.N., Kumar, K.S., Chipidza, F.E., Leeman, J.E., and Sayan, M. (2026). Association Between Cribriform Architecture and Lymphovascular Invasion in Prostate Cancer. J. Clin. Med., 15.","DOI":"10.3390\/jcm15031032"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1097\/01.ju.0000181215.41607.c3","article-title":"Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma","volume":"174","author":"Cheng","year":"2005","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"495.e491","DOI":"10.1016\/j.urolonc.2021.01.007","article-title":"Evaluation of lymphovascular invasion as a prognostic predictor of overall survival after radical prostatectomy","volume":"39","author":"Rakic","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.21774","article-title":"Lymphovascular invasion in prostate cancer: Prognostic significance in patients treated with radiotherapy after radical prostatectomy","volume":"106","author":"Brooks","year":"2006","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1464-410X.2012.11115.x","article-title":"Prognostic significance of lymphovascular invasion in radical prostatectomy specimens","volume":"110","author":"Ng","year":"2012","journal-title":"BJU Int."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Karwacki, J., Stodolak, M., Nowak, \u0141., Kie\u0142b, P., Krajewski, W., Lemi\u0144ski, A., Szyde\u0142ko, T., and Ma\u0142kiewicz, B. (2024). Preoperative Factors for Lymphovascular Invasion in Prostate Cancer: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25020856"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.urology.2025.06.063","article-title":"Revisiting the Role of Lymphovascular Invasion in Prostate Cancer: A Narrative Review","volume":"204","author":"Karwacki","year":"2025","journal-title":"Urology"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Takahashi, H., Katsuta, E., Yan, L., Tokumaru, Y., Katz, M.H.G., and Takabe, K. (2020). Transcriptomic Profile of Lymphovascular Invasion, a Known Risk Factor of Pancreatic Ductal Adenocarcinoma Metastasis. Cancers, 12.","DOI":"10.3390\/cancers12082033"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111286","DOI":"10.1016\/j.intimp.2023.111286","article-title":"A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma","volume":"127","author":"Huang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The Molecular Taxonomy of Primary Prostate Cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11684-018-0656-6","article-title":"Epithelial-to-mesenchymal transition in cancer: Complexity and opportunities","volume":"12","author":"Zhang","year":"2018","journal-title":"Front. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Pearson, G.W. (2019). Control of Invasion by Epithelial-to-Mesenchymal Transition Programs during Metastasis. J. Clin. Med., 8.","DOI":"10.3390\/jcm8050646"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10549-020-05630-5","article-title":"Lymphovascular invasion in breast cancer is associated with gene expression signatures of cell proliferation but not lymphangiogenesis or immune response","volume":"181","author":"Asaoka","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.semcancer.2012.05.003","article-title":"The epithelial-mesenchymal transition under control: Global programs to regulate epithelial plasticity","volume":"22","author":"Nieto","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/bs.ircmb.2024.06.004","article-title":"Chapter Four\u2014Role of interferon dependent and independent signaling pathways: Implications in cancer","volume":"Volume 389","author":"Mukherjee","year":"2024","journal-title":"International Review of Cell and Molecular Biology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1929005","DOI":"10.1080\/2162402X.2021.1929005","article-title":"Double-edged effects of interferons on the regulation of cancer-immunity cycle","volume":"10","author":"Zhang","year":"2021","journal-title":"OncoImmunology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.it.2015.09.007","article-title":"Interferons and the Immunogenic Effects of Cancer Therapy","volume":"36","author":"Minn","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e50162","DOI":"10.15252\/embr.202050162","article-title":"Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone","volume":"21","author":"Owen","year":"2020","journal-title":"EMBO Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1038\/s41598-022-10724-9","article-title":"Interferon-\u03b3 increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer","volume":"12","author":"Korentzelos","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Huang, J., Ojo, A., Tsao, S., Horowitz, A., Kyprianou, N., and Tsao, C.-K. (2025). Overcoming Immune Evasion in the Prostate Tumor Microenvironment: Novel Targeted Strategies to Improve Treatment Outcomes. Cancers, 17.","DOI":"10.3390\/cancers17213441"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Fan, L., Xu, G., Cao, J., Li, M., Zhang, H., Li, F., Qi, X., Zhang, X., Li, Z., and Han, P. (2021). Type I Interferon Promotes Antitumor T Cell Response in CRPC by Regulating MDSC. Cancers, 13.","DOI":"10.3390\/cancers13215574"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Xu, P., Qu, H., Yang, J.C., Wei, F., Zhao, J., Tang, M., Wang, L., Nip, C., Li, H., and Gao, A.C. (2025). Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer. Cancers, 17.","DOI":"10.3390\/cancers17193187"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12967-022-03827-4","article-title":"Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer","volume":"21","author":"Han","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Selmani, Z., Peixoto, P., Overs, A., and Hervouet, E. (2025). The Years 2015\u20132025 as a Prospective Decade for the Identification of Specific Methylation Biomarkers of Prostate Cancer. Biomolecules, 15.","DOI":"10.3390\/biom15091334"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","article-title":"Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance","volume":"10","author":"Song","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Qiao, S., Zhang, W., Su, Y., and Jiang, Y. (2022). Integrated bioinformatics analysis of IFITM1 as a prognostic biomarker and investigation of its immunological role in prostate adenocarcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1037535"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Schimmelpfennig, C., Rade, M., F\u00fcssel, S., L\u00f6ffler, D., Blumert, C., Bertram, C., Borkowetz, A., Otto, D.J., Puppel, S.H., and H\u00f6nscheid, P. (2023). Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11019-6"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e70288","DOI":"10.1002\/ctm2.70288","article-title":"Transcriptomic miRNA and mRNA signatures in primary prostate cancer that are associated with lymph-node invasion","volume":"15","author":"Bustos","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1245\/s10434-016-5153-z","article-title":"Perineural Invasion and Lymphovascular Invasion are Associated with Increased Risk of Biochemical Recurrence in Patients Undergoing Radical Prostatectomy","volume":"23","author":"Kang","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imr.13272","article-title":"Type I interferon and cancer","volume":"321","author":"Holicek","year":"2024","journal-title":"Immunol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.celrep.2014.05.045","article-title":"EZH2-Mediated Inactivation of IFN-\u03b3-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer","volume":"8","author":"Wee","year":"2014","journal-title":"Cell Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/bioinformatics\/bty895","article-title":"Heavy-tailed prior distributions for sequence count data: Removing the noise and preserving large differences","volume":"35","author":"Zhu","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_48","first-page":"100141","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1039\/C5MB00663E","article-title":"ReactomePA: An R\/Bioconductor package for reactome pathway analysis and visualization","volume":"12","author":"Yu","year":"2016","journal-title":"Mol. Biosyst."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: A comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2167\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:56:31Z","timestamp":1772517391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27052167"],"URL":"https:\/\/doi.org\/10.3390\/ijms27052167","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]}}}